Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q1 EPS of ($0.50), $0.01 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $14.75 million versus the consensus estimate of $14.98 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.